New Delhi, Apr 11 (UNI) Centre has prohibited the exports of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the COVID situation in the country improves.
'India is witnessing a recent surge in COVID cases. As on April 11, there are 11.08 lakh active COVID cases and they are steadily increasing. This has led to a sudden spike in demand for Injection Remdesivir used in treatment of COVID patients. There is a potential of further increase in this demand in the coming days,' the Union Ministry of Health and Family Welfare said in a statement here on Sunday.
Seven Indian companies are producing Injection Remdesivir under voluntary licensing agreement with M/s Gilead Sciences, USA. They have an installed capacity of about 38.80 lakh units per month.